However, screening with CA125 and transvaginal ultrasound is recommended by the National Comprehensive Cancer Network guidelines and the SGO for women with known hereditary syndromes of ovarian cancer (such as women with germline BRCA1/2 mutations), even though there is currently no evidence that this screening strategy improves survival in elevated risk populations (Schorge et al., 2010). This evidence concerns the gene BRCA1 and ovarian carcinoma.